We’ve recently updated our electronic health record and other systems to better support your care. We appreciate your patience and understanding as we work through this change and look forward to caring for you!
Study Title: A prospective, multi-center, single-blind, randomized (1:1), noninferiority study comparing clinical outcomes of the Virtue® Sirolimus AngioInfusion Balloon (SAB) to the AGENT Paclitaxel Drug-Coated Balloon (DCB) in the treatment of coronary artery in-stent restenosis (ISR).
PI/Lead Researcher: Amir Lotfi, MD
IRB#: BH26-081
NCT#: NCT07045194
Location: Baystate Medical Center
Primary Sponsor: Orchestra BioMed, Inc.
Purpose: The purpose of this study is to compare how well two device/drug combination products open a blocked area in a heart artery. Eligible participants will have follow-up visits via phone call for 5 years after the procedure.
Eligibility
Inclusion Criteria:
Received a Drug-Eluting (DES) or Bare Metal Stent (BMS) in a Percutaneous Coronary Intervention (PCI) over 30 days ago.
Exclusion Criteria:
Are currently receiving dialysis.
Have an intolerance to antiplatelet drugs, anticoagulants required for the procedure.
Dates and Time Commitment
Recruitment Status: Active
Active Date Opened to Enrollment/Recruitment: 08/27/2026
Trial Start Date: 08/27/2026 Trial Expire Date: 06/02/2027 Time Commitment: 5 years from the day of the procedure. All follow-up visits are conducted over the phone. These calls will be completed at 1 month, 6 months, 1 year, 2, years, 3 years, 4 years, and 5 years after your study treatment.
